Esophageal Carcinoma in El-Gharbia Governorate, Egypt: Clinico-Epidemiologic Study and Treatment Outcome
International Journal of Clinical Oncology and Cancer Research
Volume 2, Issue 1, February 2017, Pages: 15-21
Received: Jan. 25, 2017; Accepted: Feb. 10, 2017; Published: Mar. 2, 2017
Views 1706      Downloads 86
Ahmed Abdelmabood Zeeneldin, Medical Oncology, Hematology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Magdy Saber, Medical Oncology, Hematology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Ashraf Hamed Hassouna, Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
Sara Ahmed Farag, Tanta Cancer Center, Ministry of Health, Gharbia, Egypt
Article Tools
Follow on us
Background: Esophageal carcinoma (EC) is rare and little is known about them in Egypt. Gharbia population-based cancer registry (GPBCR) is the first population-based cancer registry in Egypt located in the Tanta Cancer Center (TCC). It has been successfully functioning since January 1999, covering 4.1 million population. We aimed to determine EC characteristics in Egyptian patients. Materials and methods: Retrospective analysis of 70 cases with ECs, who were identified in GPBCR between January 2000 and December 2002; of whom 35 were treated at TCC. Patients’ medical records were reviewed regarding clinic-epidemiologic, treatment, and follow-up data. Results: Median age was 60 years (range, 18-83 years) with male predominance (63%). Dysphagia was the most common presentation (75%). The lower third was the commonest site (55%) followed by the middle third (25%). Squamous cell carcinoma (SCC) was the commonest histology (66%) followed by adenocarcinoma (AC; 24%). Majority of ACs (70%) were located in the lower esophagus while SCC had no site of preference (p=0.04). Less than one third of patients were candidates for radical treatment while the majority of patients received palliative and supportive treatment. Surgery, radiotherapy and chemotherapy were employed in 43%, 20%, and 34% of patients respectively. The median progression-free survival and overall survival were 6 and 7 months, respectively. Site, histology, stage and treatment modality had no significant impact on survival. Conclusions: Esophageal carcinoma in Gharbia Governorate, Egypt is characterized by predominance of male gender, lower third location and squamous histology. Overall and progression free survivals are dismal.
Egypt, Gharbia Population-Based Cancer Registry, Esophageal Cancer
To cite this article
Ahmed Abdelmabood Zeeneldin, Magdy Saber, Ashraf Hamed Hassouna, Sara Ahmed Farag, Esophageal Carcinoma in El-Gharbia Governorate, Egypt: Clinico-Epidemiologic Study and Treatment Outcome, International Journal of Clinical Oncology and Cancer Research. Vol. 2, No. 1, 2017, pp. 15-21. doi: 10.11648/j.ijcocr.20170201.14
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Parkin DM, Bray F, Ferla J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin 2015; 65: 87-108.
Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1404-13.
Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002; 37: 1359-65.
Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, et al. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-2011) and predictions to 2015. Ann Oncol 2014; 25: 283-290.
Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007; 17: 38-44.
Mariette C, Finzi L, Piessen G. Van Seuningen I, Triboulet JP. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 2005; 29: 39-45.
Alexandrou A, Davis PA, Law S, Murthy S, Whooley BP, Wong J. Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences. Dis Esophagus 2002;15: 290-5.
Parkin DM, Läärä E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41: 184-97.
Boersma E, Harrington RA, Moliterno DJ, White H, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 2002; 360: 342-3.
Marjani HA, Biramijamal F, Hossein-Nezhad A, Islami F, Pourshmas A, Semnani S. Prevalence of esophageal cancer risk factors among Turkmen and non-Turkmen ethnic groups in a high incidence area in Iran. Arch Iran Med 2010; 13: 111-5.
Thorban S, Roder JD, Nekarda H, Funk A, Siewert JR, Pantel K. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 1996; 88: 1222-7.
Freedman L, Edwards BK, Ries LAG, Al-Kayed S, Barchana M, Ibrahim AS, Komodiki C, Young JL (2006) Overview and summary data. In: Freedman LS, Edwards BK, Ries LAG, Young JL (eds) Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER, NIH Pub. No. 06-5873, Bethesda, MD, pp 1–27.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359-86.
Salim EI, Moore MA, Al-Lawati JA, Al-Sayyad J, Bazawir A, Bener A, et al. Cancer Epidemiology and Control in the Arab World - Past, Present and Future. Asian Pacific J Cancer Prev 2009;10: 3-16.
Ekström AM, Signorello LB, Hansson LE, Bergström R, Lindgren A, Nyrén O. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 1999;91: 786-90.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-6.
Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus 2008; 21: 322-7.
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005;113: 456-63.
Lu CL, Lang HC, Luo JC, Liu CC, Lin HC, Chang FY, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control 2010; 21: 269-74.
Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010; 19: 1468-70.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 1995; 109: 130-8.
Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234: 360-7.
Hölscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 1995; 76: 178-86.
Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-8.
Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, et al. Long-term Outcome of 2920 Patients with Cancers of the Esophagus and Esophagogastric Junction: Evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee Staging System. Ann Surg 2011; 253: 689-98.
Koppert LB, Janssen-Heijnen ML, Louwman MW, Lemmens VE, Wijnhoven BP, Tilanus HW, et al. Comparison of comorbidity prevalence in esophageal and gastric carcinoma patients: a population-based study. Eur J Gastroenterol Hepatol 2004; 16: 681-8.
American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p. 103.
Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-7.
Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-9.
Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236: 177-83.
Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230: 392-400.
Rajagopalan J, Triadafilopoulos G. Ring(s)-related esophageal meat bolus impaction: biopsy first, dilate later. Dis Esophagus 2009;22: E14-6.
Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg 1980;67: 457-61.
Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-37.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186